BidaskClub upgraded shares of NxStage Medical (NASDAQ:NXTM) from a strong sell rating to a sell rating in a report released on Monday.
Several other equities analysts have also recently commented on the stock. Zacks Investment Research cut shares of NxStage Medical from a hold rating to a sell rating in a research note on Tuesday, November 14th. Canaccord Genuity reaffirmed a hold rating and set a $30.00 price objective on shares of NxStage Medical in a research note on Tuesday, October 17th. Northland Securities reaffirmed a hold rating and set a $30.00 price objective on shares of NxStage Medical in a research note on Wednesday, November 8th. Finally, ValuEngine cut shares of NxStage Medical from a hold rating to a sell rating in a research note on Friday, February 2nd. Two research analysts have rated the stock with a sell rating and nine have given a hold rating to the company. The stock presently has a consensus rating of Hold and an average price target of $30.25.
NxStage Medical (NXTM) opened at $23.15 on Monday. NxStage Medical has a 12 month low of $20.45 and a 12 month high of $30.80.
In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of NxStage Medical stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $25.73, for a total transaction of $90,055.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 10,500 shares of company stock valued at $265,860. 4.70% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the business. Public Employees Retirement Association of Colorado bought a new stake in NxStage Medical during the fourth quarter valued at approximately $128,000. Prudential Financial Inc. bought a new stake in NxStage Medical during the third quarter valued at approximately $202,000. Amalgamated Bank lifted its position in NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after purchasing an additional 553 shares during the last quarter. Koch Industries Inc. bought a new stake in NxStage Medical during the second quarter valued at approximately $227,000. Finally, Suntrust Banks Inc. lifted its position in NxStage Medical by 2.3% during the second quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after purchasing an additional 209 shares during the last quarter. Institutional investors and hedge funds own 85.56% of the company’s stock.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.